Leicester School of Pharmacy, Faculty of Health and Life Sciences, De Montfort University, Leicester, United Kingdom.
University of Misan, College of Medicine, Misan, Amara, Iraq.
PLoS One. 2021 May 14;16(5):e0251115. doi: 10.1371/journal.pone.0251115. eCollection 2021.
This study evaluated the adherence to prescribed cardiovascular therapy medications among cardiovascular disease patients attending clinics in Misan, Amara, Iraq. Mixed methods were used to assess medication adherence comprising the Arabic version of the eight-item Morisky Medication Adherence Scale (MMAS-8) and determination of drug concentrations in patient dried blood spot (DBS) samples by liquid chromatography-high resolution mass spectrometry. Three hundred and three Iraqi patients (median age 53 years, 50.5% female) who had been taking one or more of the nine commonly prescribed cardiovascular medications (amlodipine, atenolol, atorvastatin, bisoprolol, diltiazem, lisinopril, losartan, simvastatin and valsartan) for at least six months were enrolled. For each patient MMAS-8 scores were determined alongside drug concentrations in their dried blood spot samples. Results from the standardized questionnaire showed that adherence was 81.8% in comparison with 50.8% obtained using the laboratory-based microsample analysis. The agreement between the indirect (MMAS-8) and direct (DBS analysis) assessment approaches to assessing medication adherence showed significantly poor agreement (kappa = 0.28, P = 0.001). The indirect and direct assessment approaches showed no significant correlation between nonadherence to prescribed cardiovascular pharmacotherapy and age and gender, but were significantly associated with the number of medications in the patient's treatment regimen (MMAS-8: Odds Ratio (OR) 1.947, 95% CI, P = 0.001; DBS analysis: OR 2.164, 95% CI, P = 0.001). The MMAS-8 results highlighted reasons for nonadherence to prescribed cardiovascular pharmacotherapy in this patient population whilst the objective DBS analysis approach gave valuable information about nonadherence to each medication in the patient's treatment regimen. DBS sampling, due its minimally invasive nature, convenience and ease of transport is a useful alternative matrix to monitor adherence objectively in Iraq to cardiovascular pharmacotherapy. This information combined with MMAS-8 can provide clinicians with an evidence-based novel approach to implement intervention strategies to optimise and personalise cardiovascular pharmacotherapy in the Iraqi population and thereby improve patient health outcomes.
这项研究评估了在伊拉克米桑省阿玛拉诊所就诊的心血管疾病患者对心血管治疗药物的遵医嘱情况。研究采用混合方法评估药物依从性,包括阿拉伯语版的八项Morisky 药物依从性量表(MMAS-8)和通过液相色谱-高分辨率质谱法测定患者干血斑(DBS)样本中的药物浓度。共纳入 303 名伊拉克患者(中位年龄 53 岁,50.5%为女性),他们至少服用了九种常用心血管药物中的一种或多种(氨氯地平、阿替洛尔、阿托伐他汀、比索洛尔、地尔硫卓、赖诺普利、氯沙坦、辛伐他汀和缬沙坦)至少六个月。为每位患者测定 MMAS-8 评分,并同时测定其干血斑样本中的药物浓度。标准化问卷结果显示,与通过实验室微样本分析得出的 50.8%相比,依从率为 81.8%。间接(MMAS-8)和直接(DBS 分析)评估方法评估药物依从性的结果显示一致性很差(kappa=0.28,P=0.001)。间接和直接评估方法显示,未遵医嘱进行心血管药物治疗与年龄和性别之间无显著相关性,但与患者治疗方案中的药物数量显著相关(MMAS-8:比值比(OR)1.947,95%置信区间,P=0.001;DBS 分析:OR 2.164,95%置信区间,P=0.001)。MMAS-8 结果突出了该患者群体中未遵医嘱进行心血管药物治疗的原因,而客观的 DBS 分析方法提供了关于患者治疗方案中每种药物的不依从的有价值信息。DBS 采样因其微创性、便利性和易于运输,是一种有用的替代基质,可以在伊拉克客观地监测心血管药物治疗的依从性。这些信息与 MMAS-8 相结合,可以为临床医生提供一种基于证据的新方法,以实施干预策略,优化和个性化伊拉克人群的心血管药物治疗,从而改善患者的健康结局。